<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _____ TO _____
COMMISSION FILE NUMBER 1-9898
------
ORGANOGENESIS INC.
(Exact name of registrant as specified in its charter)
DELAWARE 04-2871690
----------------------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification number)
150 DAN ROAD, CANTON, MA 02021
-----------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 575-0775
______________________
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes ( X ) No ( )
The number of shares outstanding of registrant's Common Stock, par value $.01
per share, at August 5, 1997 was 18,069,786 shares.
1
<PAGE>
ORGANOGENESIS INC.
INDEX
-----
Page
PART I - FINANCIAL INFORMATION Number
- - ------------------------------ ------
Item 1 - Financial Statements
Consolidated Balance Sheets
at June 30, 1997 and December 31, 1996..................... 3
Consolidated Statements of Operations
for the three and six months ended June 30, 1997 and 1996.. 4
Consolidated Statements of Cash Flows
for the six months ended June 30, 1997 and 1996............ 5
Notes to Consolidated Financial Statements............................. 6
Item 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations..................... 8
PART II - OTHER INFORMATION
- - ---------------------------
Item 1 - Legal Proceedings................................................. *
Item 2 - Changes in Securities............................................. *
Item 3 - Defaults upon Senior Securities................................... *
Item 4 - Submission of Matters to a Vote of Security Holders............... 11
Item 5 - Other Information................................................. 11
Item 6 - Exhibits and Reports on Form 8-K.................................. 11
Signatures................................................................. 12
* No information provided due to inapplicability of item
2
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS
ORGANOGENESIS INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
<TABLE>
<CAPTION>
June 30, 1997 December 31,
(unaudited) 1996
-------------- ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 1,121 $ 399
Investments 8,184 14,041
Other current assets 870 703
------- -------
10,175 15,143
Property and equipment, net 7,113 7,204
Other assets 91 89
------- -------
$17,379 $22,436
======= =======
LIABILITIES
Current liabilities:
Accounts payable $ 840 $ 1,220
Accrued expenses 1,621 2,667
------- -------
2,461 3,887
Deferred rent payable 50 71
STOCKHOLDERS' EQUITY
Preferred stock, par value $1.00; authorized
1,000,000 shares:
Series A Convertible Preferred;
designated 250,000 shares;
all have been issued and converted - -
Series B Junior Participating;
designated 50,000 shares;
no shares issued and outstanding - -
Common stock, par value $.01; authorized
40,000,000 shares: issued and outstanding
18,023,721 and 17,865,431 shares as of
June 30, 1997 and December 31, 1996, respectively 180 179
Additional paid-in capital 92,528 85,478
Accumulated deficit (77,840) (67,179)
-------- --------
Total stockholders' equity 14,868 18,478
-------- --------
$ 17,379 $ 22,436
======== ========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
3
<PAGE>
ORGANOGENESIS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except share data)
<TABLE>
<CAPTION>
For the For the
Three Months Six Months
Ended June 30, Ended June 30,
---------------------------- -------------------------
1997 1996 1997 1996
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Revenues:
Research and development support
from related party $ 2,500 $ 2,187 $ 2,500 $ 4,000
Product sales to related party, royalties
and other income 206 - 300 21
Interest income 102 239 269 491
----------- ----------- ----------- -----------
Total revenues 2,808 2,426 3,069 4,512
----------- ----------- ----------- -----------
Costs and expenses:
Research and development 3,309 2,500 6,333 5,288
General and administrative 912 1,018 1,841 2,075
Noncash charge for stock option extension 5,555 - 5,555 -
----------- ----------- ----------- -----------
Total costs and expenses 9,776 3,518 13,729 7,363
----------- ----------- ----------- -----------
Net loss $ (6,968) $ (1,092) $ (10,660) $ (2,851)
=========== =========== =========== ===========
Net loss per common share $(.39) $(.06) $(.59) $(.16)
=========== =========== =========== ===========
Weighted average number of
common shares outstanding 18,003,167 17,526,869 17,952,845 17,466,208
=========== =========== =========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
4
<PAGE>
ORGANOGENESIS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
<TABLE>
<CAPTION>
For the
Six Months
Ended June 30
---------------------
1997 1996
---------- ---------
<S> <C> <C>
Cash flows from operating activities:
Net loss $(10,660) $(2,851)
Adjustments to reconcile net loss to
cash used in operating activities:
Depreciation 682 505
Issuance of stock options 50 -
Noncash charge for stock option extension 5,555 -
Changes in assets and liabilities:
Other current assets (167) (3)
Other assets (2) (1)
Accounts payable (380) 13
Accrued expenses (1,046) (45)
Deferred revenue - 2,500
Deferred rent payable (21) (21)
-------- -------
Cash provided by (used in) operating activities (5,989) 97
-------- -------
Cash flows from investing activities:
Capital expenditures (591) (312)
Purchases of investments (2,000) (8,750)
Sales/maturities of investments 7,857 3,970
-------- -------
Cash provided by (used in) investing activities 5,266 (5,092)
-------- -------
Cash flows from financing activities:
Proceeds from sale of common stock - 5,000
Proceeds from exercise of warrants 139 488
Proceeds from exercise of stock options 1,306 277
-------- -------
Cash provided by financing activities 1,445 5,765
-------- -------
Increase in cash and cash equivalents 722 770
Cash and cash equivalents, beginning of period 399 2,569
-------- -------
Cash and cash equivalents, end of period $ 1,121 $ 3,339
======== =======
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
5
<PAGE>
ORGANOGENESIS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
This Form 10-Q and other public filings or statements made by the Company from
time to time which concern the Company's business outlook; future financial
performance; anticipated profitability, revenues, expenses or capital
expenditures; future funding under collaborative agreement; and statements
concerning expectations as to any future events, as well as other statements
which are not historical fact, are forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 and involve risks and
uncertainties. The Company's actual results may differ significantly from the
results discussed in these forward-looking statements. Factors that might cause
such a difference include, but are not limited to, those discussed under the
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" section in this report and included in publicly available filings
with the Securities and Exchange Commission, such as the Company's Annual Report
on Form 10-K for the year ended December 31,1996.
1. Basis of Presentation:
----------------------
The accompanying unaudited consolidated financial statements of Organogenesis
Inc. (the "Company"), have been prepared in accordance with generally accepted
accounting principles for interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they
do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, the accompanying consolidated financial statements
include all adjustments, consisting of normal recurring adjustments, necessary
for a fair presentation of the financial position, results of operations and
changes in cash flows for the periods presented. The results of operations for
the three and six months ended June 30, 1997 are not necessarily indicative of
the results to be expected for the year ending December 31, 1997.
These financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in the Company's
Annual Report on Form 10-K for the year ended December 31, 1996 as filed with
the Securities and Exchange Commission.
2. New Accounting Pronouncements:
------------------------------
In February 1997, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standards No. 128, "Earnings Per Share" ("SFAS
128"). SFAS 128 establishes standards for computing and presenting earnings per
share and applies to entities with publicly held common stock or potential
common stock. SFAS 128 is effective for fiscal years ending after December 15,
1997, including interim periods. Earlier application is not permitted. When
adopted, SFAS 128 will require restatement of prior years' earnings per share
data. The Company plans to adopt SFAS 128 for its fiscal year ended December
31, 1997 and does not expect the effect of its adoption would be materially
different from the amounts presented in the accompanying statements of
operations.
6
<PAGE>
In June 1997, the Financial Accounting Standards Board (FASB) issued Statement
of Financial Accounting Standards No. 130, "Reporting Comprehensive Income"
("SFAS 130"). SFAS 130 requires that changes in comprehensive income be shown
in a financial statement that is displayed with the same prominence as other
financial statements. SFAS 130 is effective for fiscal years beginning after
December 15, 1997. The Company does not expect the adoption of SFAS 130 to
materially effect the financial statement presentation.
3. Collaborative Agreement:
------------------------
In January 1996, the Company and Novartis AG ("Novartis" or "related party"),
entered into an agreement granting Novartis exclusive global marketing rights to
the Company's lead product, Apligraf/TM/. Under the agreement, Novartis is
responsible for Apligraf/TM/ sales and marketing costs worldwide, as well as all
clinical trials, registrations and patent costs outside the U.S. The Company
will supply Novartis' global requirements for Apligraf/TM/ and will receive both
a per unit manufacturing payment and royalty revenues on product sales. Novartis
has agreed to provide the Company up to $37,500,000 in equity investment,
research support and milestone payments, of which $2,500,000 has been received
in 1997 and $11,500,000 was received in 1996. The remaining payments will be
received based upon achievement of specified events.
4. Stockholders' Equity:
---------------------
On April 14, 1997, the Board of Directors declared a 25% stock dividend for
stockholders of record on April 25, 1997. The stock dividend was payable on May
2, 1997 and resulted in the issuance of 3,596,150 additional shares of Common
Stock. All related data in the consolidated financial statements and notes
reflect the stock dividend for all periods presented.
During the first quarter of 1997, the Company received proceeds of $139,125
related to the exercise of warrants to purchase Common Stock which were issued
as part of a public offering in July 1995. Each warrant allows for the purchase
of one share of Common Stock at an exercise price of $12.72 per share. On July
21, 1997, the Company gave notice of redemption with respect to all of its
outstanding Common Stock Purchase Warrants issued during the July 1995 public
offering. Any Common Stock Purchase Warrants not exercised before August 21,
1997 will be redeemed for $.01 per share. At June 30, 1997, there were 348,438
Common Stock Purchase Warrants outstanding with an exercise price of $12.72 per
share.
5. Stock Option:
-------------
On May 5, 1997, the Board of Directors voted to extend the term of an option to
purchase 468,750 shares of Common Stock at an exercise price of $4.80 granted to
an officer of the Company in 1987. The extension of this option requires a new
measurement date for valuing the option, resulting in a non-cash compensation
charge of $5,555,000 recorded in the second quarter of 1997. The option is
fully exercisable and the shares have been reserved for issuance.
7
<PAGE>
ORGANOGENESIS INC.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Overview:
- - ---------
Organogenesis Inc. (the "Company") designs, develops and manufactures medical
therapeutics containing living cells and/or natural connective tissue
components. The Company's products are designed to promote the establishment
and growth of new tissues to restore, maintain or improve biological function.
The Company is subject to risks common to entities in the biotechnology
industry, including, but not limited to, development by the Company's
competitors of new technologies or products that are more effective than the
Company's, risks of failure of clinical trials, dependence on and retention of
key personnel, protection of proprietary technology, compliance with U.S. Food
and Drug Administration ("FDA") regulations and similar foreign regulatory
bodies, continued availability of raw material for the Company's products,
availability of product liability insurance upon commercialization of the
Company's products, ability to transition from pilot-scale manufacturing to
full-scale commercial production of products, ability to recover the investment
in property and equipment, uncertainty as to the availability of additional
capital on acceptable terms, if at all, and the demand for the Company's
products, if and when approved.
In April 1997, the Company's lead product, Apligraf/TM/ manufactured human skin
equivalent, was approved for marketing in Canada. The product was commercially
launched in Canada by Novartis Pharmaceuticals Canada, Inc., an affiliate of
Novartis Pharmaceuticals AG, in August 1997. Novartis has global Apligraf/TM/
marketing rights. The Apligraf/TM/ premarket approval application (PMA) for
venous ulcers is currently pending at the FDA. Novartis is also pursuing
additional international registrations for Apligraf/TM/.
Results of Operations may vary significantly from quarter to quarter depending
on, among other factors, the progress of the Company's research and development
efforts, the receipt of milestone and research and development support payments,
if any, from Novartis, product sales, the timing of certain expenses and the
establishment of additional collaborative agreements, if any.
Results of Operations:
- - ----------------------
Revenues
Total revenues were $2,808,000 and $3,069,000 for the three and six months ended
June 30, 1997, compared to $2,426,000 and $4,512,000, for the same periods in
1996. Research and development support from Novartis was $2,500,000 for the
three and six months ended June 30, 1997, compared to $2,187,000 and $4,000,000,
for the same periods in 1996 (See "Notes to Consolidated Financial
Statements"). Other revenue increased to $206,000 and $300,000 for the three
and six months ended June 30, 1997, compared to $0 and $21,000, for the same
periods in 1996, primarily due to increased noncommercial product sales to
Novartis. Interest income decreased to $102,000 and $269,000 for the three and
six months ended June 30, 1997, compared to $239,000 and $491,000, for the same
periods in 1996, primarily due to less cash being available for investment.
8
<PAGE>
Costs and Expenses
Research and development expenses increased to $3,309,000 and $6,333,000 for the
three and six months ended June 30, 1997, compared to $2,500,000 and $5,288,000,
for the same periods in 1996, primarily due to personnel additions, expansion of
facilities, and other activities supporting Apligraf/TM/, the Company's lead
product, and other research and development programs, including the Apligraf/TM/
diabetic ulcer pivotal trial and the liver assist device research program.
General and administrative expenses decreased to $912,000 and $1,841,000 for the
three and six months ended June 30, 1997, compared to $1,018,000 and $2,075,000,
for the same periods in 1996. The decrease was primarily due to a reduction in
the use of outside services and cost containment, including legal, corporate
insurance and other corporate costs. This decrease was partially offset by an
increase in personnel costs, mostly due to new employees to support the
Company's programs.
Additionally, in May 1997, the Company incurred a one time, non-cash
compensation charge of $5,555,000 relating to the extension of the term of a
stock option held by an officer of the Company.
As a result of the net effect described above, the Company incurred a net loss
of $6,968,000, or $.39 per share, and $10,660,000, or $.59 per share, for the
three and six months ended June 30, 1997, respectively, compared to a net loss
of $1,092,000, or $.06 per share, and $2,851,000, or $.16 per share, for the
comparable 1996 periods. The Company expects to incur additional losses as its
research and development expenses and other costs continue to increase due to
factors described above.
Liquidity and Capital Resources:
- - --------------------------------
At June 30, 1997, the Company had cash, cash equivalents and investments in the
aggregate amount of $9,305,000 and working capital of $7,714,000, compared to
$14,440,000 and $11,256,000, respectively, at December 31, 1996. The primary
use of cash during the six months ended June 30, 1997 related to financing the
Company's operating activities of $5,989,000 and investing in plant expansion.
Capital expenditures increased to $591,000 for the six months ended June 30,
1997, from $312,000 for the same period in 1996, primarily due to the build-out
of the current facilities to support Apligraf/TM/ manufacturing and the
acquisition of laboratory equipment for expanded research and development
programs. The Company expects to continue to utilize funds at an increasing rate
during 1997 related to the continued expansion of Apligraf/TM/ operations and to
the advancement of the Company's product pipeline. The Company is also exploring
adding manufacturing capacity in the United States and Europe to support the
production of the Company's current and future products.
From inception, the Company has financed its operations substantially through
private and public placements of equity securities, as well as receipt of
research support and contract revenues, interest income from investments and, to
a lesser extent, sale of products and receipt of royalties. For the six months
ended June 30, 1997, financing activities provided cash of approximately
$1,445,000 from the exercise of stock options and warrants. Financing
activities provided cash of $5,765,000 for the six months ended June 30, 1996,
from a $5,000,000 equity investment received under the collaborative agreement
with Novartis (See "Collaborative Agreement" under the Notes to Consolidated
Financial Statements) and the exercise of warrants and stock options. On July
21, 1997, the Company gave notice of redemption with respect to all of its
outstanding Common Stock Purchase Warrants issued during the July 1995 public
offering.
9
<PAGE>
Novartis has agreed to provide the Company up to $37,500,000 in equity
investments, research support and milestone payments (See "Collaborative
Agreement" under the Notes to Consolidated Financial Statements), of which
$2,500,000 has been received in 1997 and $11,500,000 was received in 1996. The
remaining payments will be received based upon achievement of specified events.
The Company's operations and programs will require substantial additional
financial resources before the Company can expect to realize a net profit from
product sales. The Company may seek additional funding through private or
public placement of equity securities and expects future funding under its
collaboration with Novartis to finance Organogenesis' Apligraf/TM/-related
expenditures. Based upon its current plans, the Company believes that future
funds from Novartis, together with existing working capital, will be sufficient
to finance its operations for the foreseeable future. However, the Company's
funding requirements may change depending upon numerous factors, including
progress of the Company's research and development programs; time required to
obtain regulatory approvals in different countries; resources the Company
devotes to self-funded projects, proprietary manufacturing methods and advanced
technologies; and marketing approval in different countries of the Company's
products and, if approved, whether the products will be commercially successful.
There can be no assurances that additional funds will be available when required
on terms acceptable to the Company. If adequate funds are not available, there
would be a material adverse effect on the Company's financial condition and
results of operations.
10
<PAGE>
ORGANOGENESIS INC.
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The Company held its Annual Meeting for Stockholders on May 13, 1997. At the
meeting, Messrs. Richard S. Cresse, William J. Hopke, Bjorn R. Olsen, Ms.
Marguerite A. Piret, David T. Rovee, Anton E. Schrafl and Herbert M. Stein, were
re-elected as Directors. The vote with respect to each nominee is set forth
below:
<TABLE>
<CAPTION>
Vote For Vote Withheld
---------- -------------
<S> <C> <C>
Mr. Cresse 17,537,348 18,340
Mr. Hopke 17,537,504 18,184
Dr. Olsen 17,532,942 22,746
Ms. Piret 17,537,348 18,340
Dr. Rovee 17,537,504 18,184
Dr. Schrafl 17,537,348 18,340
Mr. Stein 17,537,035 18,653
</TABLE>
The stockholders also ratified the selection of Coopers & Lybrand L.L.P. as the
Company's independent public accountants for the 1997 fiscal year by a vote of
17,518,913 shares for, 14,112 shares against, 22,663 shares abstaining and
377,006 shares representing broker non-votes.
ITEM 5. OTHER INFORMATION
In August, 1997, Organogenesis received marketing clearance for its surgical
product, GRAFTPATCH(TM). Marketing clearance was granted under the FDA's Section
510(k) notification process. GRAFTPATCH(TM) is for use in general surgical
procedures for reinforcement of soft tissue. Approximately one million soft
tissue procedures, including hernia repair and bladder repair, are performed
each year in the U.S. Organogenesis intends to market GRAFTPATCH(TM) through a
partner with an established presence in the hospital/surgical market.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
10 Amended Non-Statutory Stock Option Agreement between the Company and
Herbert M. Stein dated April 7, 1987.
27 Financial Data Schedule
(b) The Company filed a current report on Form 8-K dated April 29, 1997
disclosing that the Board of Directors of the Company declared a 25% Common
Stock dividend whereby one share of Common Stock shall be distributed on or
about May 2, 1997 for each four shares of Common Stock held of record on
April 25, 1997.
11
<PAGE>
ORGANOGENESIS INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ORGANOGENESIS INC.
(Registrant)
Date: August 14, 1997 /S/ Herbert M. Stein
--------------- --------------------
Herbert M. Stein, Chairman
and Chief Executive Officer
(Principal Executive Officer)
Date: August 14, 1997 /S/ Donna L. Abelli
--------------- -------------------
Donna L. Abelli, Vice President Finance and
Administration, Chief Financial Officer,
Treasurer and Secretary
(Principal Financial and Accounting Officer)
12
<PAGE>
ORGANOGENESIS INC.
EXHIBIT INDEX
Exhibit No. Description of Exhibit
- - ----------- -----------------------------------------------------------
10 Amended Non-Statutory Stock Option Agreement
between the Company and Herbert M. Stein dated
April 7, 1987.
27 Financial Data Schedule
13
<PAGE>
Exhibit 10
ORGANOGENESIS INC.
AMENDED NON-STATUTORY STOCK OPTION AGREEMENT
1. Grant of Option. Organogenesis Inc., a Delaware corporation (the
"Company"), has granted to Herbert M. Stein (the "Employee"), an option to
purchase an aggregate of 468,750 shares of Common Stock, $.01 par value ("Common
Stock"), of the Company at a price of $4.80 per share, purchasable as set forth
in and subject to the terms and conditions of this Agreement.
2. Exercise of Option and Provisions for Termination.
(a) Vesting Schedule. Except as otherwise provided in this Agreement, this
option shall be immediately exercisable, in whole or in part, and shall remain
exercisable until May 7, 2002 (hereinafter the "Expiration Date"), provided that
each exercise of this option shall be evidenced by and subject to the
provisions of the Employee Non-Statutory Stock Option Exercise Agreement in
substantially the form of Exhibit I hereto (the "Exercise Agreement"). This
option may not be exercised at any time on or after the Expiration Date.
(b) Exercise Procedure. Subject to the conditions set forth in this
Agreement, this option shall be exercised by the Employee's delivery to the
Company of the Exercise Agreement, specifying the number of shares to be
purchased and the purchase price to be paid therefor and accompanied by payment
in full in accordance with Section 4. Such exercise shall be effective upon
execution by the Employee and the Company of the Exercise Agreement. The
Employee may purchase less than the number of shares covered hereby, provided
that no partial exercise of this option may be for any fractional share or for
fewer than ten whole shares.
(c) Continuous Employment Required. Except as otherwise provided in Section 3
hereof, this option may not be exercised unless the Employee, at the time he or
she exercises this option, is, and has been at all times since the date of grant
of this option, an employee of one or more of the Company, a Parent Corporation
or a Subsidiary. The term "Parent Corporation" as used in this Agreement shall
mean any corporation (other than the Company) in an unbroken chain of
corporations ending with the Company if, at the time of the granting of an
option, each of the corporations other than the Company owns stock possessing
50% or more of the combined voting power of all classes of stock in one of the
other corporations in such chain. The term "Subsidiary" as used in this
Agreement shall mean any corporation (other than the Company) in an unbroken
chain of corporations beginning with the Company if, at the time of the granting
of an option, each of the corporations other than the last corporation in the
unbroken chain owns stock possessing 50% or more of the total combined voting
power of all classes of stock in one of the other corporations in such chain.
For all purposes of this option, (i) "employment" shall be defined in accordance
with the provisions of Section 1.421-7(h) of the Income Tax Regulations or any
successor regulations, and (ii) if this option shall be assumed or a new option
substituted therefor in a transaction to which Section 425(a) of the Code
applies, employment by such assuming or substituting corporation (hereinafter
called the "Successor Corporation") or by a Parent Corporation or a Subsidiary
thereof (as defined in the Plan, respectively, but with the Successor
Corporation substituted for the Company in such definitions) shall be considered
for all purposes of this option to be employment by the Company, a Parent
Corporation or a Subsidiary, as the case may be.
(d) Exercise Period Upon Termination of Employment. If the Employee ceases to
be employed by the Company, a Parent Corporation or Subsidiary for any reason
other than death or disability or a discharge for "cause," as provided below,
the right to exercise this option shall terminate three months after such
cessation (but in no event after the Expiration Date).
(e) Exercise Period Upon Death or Disability. If the Employee dies or becomes
disabled (within the meaning of Section 22(e) (3) of the Code or any successor
provision thereto) prior to the Expiration Date while he or she is an employee
of the Company, a Parent Corporation or a Subsidiary, or if the Employee dies
within three months after
<PAGE>
the Employee ceases to be an employee of any of the
foregoing entities (other than as the result of a discharge for "cause" as
specified in paragraph (f) below), this option shall be exercisable, within the
period of one year following the date of death or disability of the Employee
(but in no event after the Expiration Date), by the Employee or by the person to
whom this option is transferred by will or the laws of descent and distribution.
Except as otherwise indicated by the context, the term "Employee", as used in
this option, shall be deemed to include the estate of the Employee or any person
who acquires the right to exercise this option by bequest or inheritance or
otherwise by reason of the death of the Employee.
(f) Discharge for Cause. If the Employee prior to the Expiration Date, ceases
his or her employment with the Company, a Parent Corporation or a Subsidiary
because he or she is discharged for "cause" (as defined below), the right to
exercise this option shall terminate immediately upon such cessation of
employment. "Cause" shall mean willful misconduct in connection with the
Employee's employment or willful failure to perform his or her employment
responsibilities in the best interests of his or her employer, as determined by
the Company, which determination shall be conclusive.
3. Payment of Purchase Price.
(a) Method of Payment. Payment of the purchase price for shares purchased
upon exercise of this option shall be made by delivery to the Company of cash or
a check to the order of the Company in an amount equal to the purchase price of
such shares, or by delivery to the Company of shares of Common Stock of the
Company then owned by the Employee having a fair market value equal in amount to
the purchase price of such shares, or by any combination of such methods of
payment.
(b) Valuation of Shares Tendered in Payment of Purchase Price. For the
purposes hereof, the fair market value of any share of the Company's Common
Stock which may be delivered to the Company in exercise of this option shall be
determined in good faith by the Board of Directors of the Company.
(c) Delivery of Shares Tendered in Payment of Purchase Price. If the Employee
exercises options by delivery of shares of Common Stock of the Company, the
certificate or certificates representing the shares of Common Stock of the
Company to be delivered shall be duly executed in blank by the Employee or shall
be accompanied by a stock power duly executed in blank suitable for purposes of
transferring such shares to the Company. Fractional shares of Common Stock of
the Company will not be accepted in payment of the purchase price of shares
acquired upon exercise of this option.
(d) Use of Statutory Option Stock. Notwithstanding the foregoing, "statutory
option stock" (as defined below) may not be tendered in payment of the exercise
price of this option if the stock to be so tendered has not, at the time of
tender, been held by the Employee for the applicable minimum statutory holding
period required to receive the tax benefits afforded under Section 421(a) of the
Code with respect to such stock. As used above, the term "statutory option
stock" means stock acquired through the exercise of a qualified stock option,
incentive stock option, restricted stock option or an option granted under an
employee stock purchase plan. The tender of statutory option stock in payment
of the exercise price of this option shall be accompanied by written proof (in a
form satisfactory to the Company) that such stock has been held by the Employee
for the applicable minimum statutory holding period.
4. Delivery of Shares. The Company shall, upon each exercise of this option
and satisfaction of all conditions set forth in this option make prompt delivery
of such shares to the Employee in accordance with the provisions of the Exercise
Agreement, provided that if any law or regulation requires the Company to take
any action with respect to such shares before the issuance thereof, then the
date of delivery of such shares shall be extended for the period necessary to
complete such action. No shares shall be issued and delivered upon exercise of
any option unless and until, in the opinion of counsel for the Company, any
applicable registration requirements of the Securities Act of 1933, any
applicable listing requirements of any national securities exchange on which
stock of the same class is then listed, and any other requirements of law or of
any regulatory bodies having jurisdiction over such issuance
2
<PAGE>
and delivery, shall have been fully complied with. Any certificate or
certificates evidencing shares purchased upon exercise of any option may bear a
legend, in such form as the Company shall determine, indicating that such shares
are subject to the restrictions on transfer, the repurchase rights and other
provisions of the Exercise Agreement.
5. Nontransferability of Option. Except as provided in paragraph (e) of
Section 2 or as otherwise deemed appropriate by the Board of Directors of the
Company, this option is personal and no rights granted hereunder may be
transferred, assigned, pledged or hypothecated in any way (whether by operation
of law or otherwise) nor shall any such rights be subject to execution,
attachment or similar process. Upon any attempt to transfer, assign, pledge,
hypothecate or otherwise dispose of this option or of such rights other than as
provided herein, or upon the levy of any attachment or similar process upon this
option or such rights, this option and such rights shall, at the election of the
Company, become null and void.
6. No Special Employment Rights. Nothing contained in this option shall be
construed or deemed by any person under any circumstances to bind the Company or
any Parent Corporation or Subsidiary to continue the employment of the Employee
for the period within which this option may be exercised. However, during the
period of the Employee's employment, the Employee shall render diligently and
faithfully the services which are assigned to the Employee from time to time by
the Board of Directors or by the executive officers of the Company or any Parent
Corporation or Subsidiary and shall at no time take any action which, directly
or indirectly, would be inconsistent with the best interests of the foregoing
entities.
7. Rights as a Shareholder. The Employee shall have no rights as a
shareholder with respect to any shares which may be purchased by exercise of
this option unless and until a certificate representing such shares is duly
issued and delivered to the Employee. No adjustment shall be made for dividends
or other rights for which the record date is prior to the date such stock
certificate is issued.
8. Recapitalization. In the event that the outstanding shares of Common
Stock of the Company are changed into, or exchanged for, a different number or
kind of shares or other securities of the Company by reason of any
recapitalization, reclassification, stock split, stock dividend, combination or
subdivision, appropriate adjustment shall be made in the number and kind of
shares to which this option shall be exercisable. Such adjustment to this
option shall be made without change in the total price applicable to the
unexercised portion of this option and a corresponding adjustment in the option
price per share shall be made. No such adjustment shall be made which would,
within the meaning of any applicable provisions of the Code, constitute a
modification, extension or renewal of this option or a grant of additional
benefits to the Employee.
9. Reorganization. In case the Company is merged or consolidated with
another corporation and the Company is not the surviving corporation, or in case
all or substantially all of the assets or more than 50% of the outstanding
voting stock of the Company is acquired by any other corporation, or in case of
a reorganization or liquidation of the Company, prior to the Expiration Date or
termination of this option, the Company shall, with respect to this option or
any unexercised portion hereof, either (i) make appropriate provision for the
protection of any such outstanding options by the substitution on an equitable
basis of appropriate stock of the Company, or of the merged, consolidated or
otherwise reorganized corporation which will be issuable in respect to the
shares of Common Stock of the Company, provided that no additional benefits
shall be conferred upon the Employee as a result of such substitution and
further provided that the excess of the aggregate fair market value of the
shares subject to the options immediately after such substitution over the
purchase price thereof is not more than the excess of the aggregate fair market
value of the shares subject to such options immediately before such substitution
over the purchase price thereof or (ii) upon written notice to the Employee,
provide that the unexercised portion of this option must be exercised within a
specified number of days of the date of such notice or it will be terminated.
3
<PAGE>
10. Withholding Taxes. The Company's obligation to deliver shares upon the
exercise of this option shall be subject to the Employee's satisfaction of all
applicable federal, state and local income and employment tax withholding
requirements.
11. Investment Representations; Legend.
(a) Representations. The Employee represents, warrants and covenants that:
(i) Any shares purchased upon exercise of this option shall be acquired
for the Employee's account for investment only and not with a view to, or for
sale in connection with, any distribution of the shares in violation of the
Securities Act of 1933 (the "Securities Act") or any rule or regulation under
the Securities Act.
(ii) The Employee has had such opportunity as he or she has deemed
adequate to obtain from representatives of the Company such information as is
necessary to permit the Employee to evaluate the merits and risks of his or
her investment in the Company.
(iii) The Employee is able to bear the economic risk of holding shares
acquired pursuant to the exercise of the option for an indefinite period.
(iv) The Employee understands that (A) the shares acquired pursuant to the
exercise of the option are not, as of the Grant Date, registered under the
Securities Act and are "restricted securities" within the meaning of Rule 144
under the Securities Act; (B) such shares cannot be sold, transferred or
otherwise disposed of unless they are subsequently registered under the
Securities Act or an exemption from registration is then available; (C) in any
event, the exemption from registration under Rule 144 will not be available
for at least two years and even then will not be available unless a public
market then exists for the Common Stock, adequate information concerning the
Company is then available to the public and other terms and conditions of Rule
144 are complied with; and (D) there is now no registration statement on file
with the Securities and Exchange Commission with respect to the shares which
may be acquired pursuant to the exercise of this option and the Company has no
obligation to register any shares acquired pursuant to the exercise of this
option under the Securities Act.
By making payment upon exercise of this option, the Employee shall be deemed to
have reaffirmed, as of the date of such payment, the representations made in
this Section 11.
(b) Legend on Stock Certificates. Unless the shares of Common Stock to be
issued to the Employee hereunder have previously been registered under the
Securities Act of 1933, all stock certificates representing shares of Common
Stock issued to the Employee upon exercise of this option shall have affixed
thereto a legend substantially in the following form, in addition to any other
legends required by applicable state law:
"The shares of stock represented by this certificate have not been
registered under the Securities Act of 1933 and may not be transferred, sold
or otherwise disposed of in the absence of an effective registration
statement with respect to the shares evidenced by this certificate, filed and
made effective under the Securities Act of 1933, or an opinion of counsel
satisfactory to the Company to the effect that registration under such Act is
not required."
4
<PAGE>
12. Miscellaneous.
(a) Except as provided herein, this option may not be amended or otherwise
modified unless evidenced in writing and signed by the Company and the
Employee.
(b) All notices under this option shall be mailed or delivered by hand to the
parties at their respective addresses set forth beneath their names below or at
such other address as may be designated in writing by either of the parties to
one another.
(c) This option shall be governed by and construed in accordance with the
laws of the Commonwealth of Massachusetts.
ORGANOGENESIS INC.
By:
-----------------------------------
Title:
-----------------------------------
Address: 150 Dan Road
Canton, MA 02021
Date of Original Grant:
April 7, 1987
EMPLOYEE'S ACCEPTANCE
The undersigned hereby accepts the foregoing Agreement and agrees to the terms
and conditions thereof.
EMPLOYEE
-----------------------------------
Herbert M. Stein
Address: 2800 South Ocean Boulevard
Boca Raton, FL 33432
5
<PAGE>
EXHIBIT I
ORGANOGENESIS INC.
NON-STATUTORY STOCK OPTION EXERCISE AGREEMENT
AGREEMENT made this day of 19 , between
Organogenesis Inc. a
Delaware corporation (the "Company"), and (the "Employee").
WHEREAS, on April 7, 1987 (the "Grant Date") the Company granted to the
Employee, pursuant to a certain Non-Statutory Stock Option Agreement between the
Company and the Employee, which Option Agreement was amended as of May 5, 1997
(as amended, the "Option Agreement"), a Stock Option ("the Option") to purchase
shares of its Common Stock;
WHEREAS, the Employee desires to exercise the Option;
Now, THEREFORE, for valuable consideration, receipt of which is acknowledged,
the parties hereto agree as follows:
1. Exercise of Option; Purchase of Shares. The Employee hereby exercises his
Option and agrees to purchase, subject to the terms and conditions set forth in
this Agreement, shares (the "Shares") of common stock,
$.01 par value, of the Company ("Common Stock"), at a purchase price of $4.80
per share. The aggregate purchase price for the Shares shall be paid by the
Employee by check payable to the order of the Company or such other method as
may be acceptable to the Company. Upon receipt by the Company of payment for the
Shares, the Company shall issue to the Employee one or more certificates in the
name of the Employee for that number of shares purchased by the Employee. The
Employee agrees that the Shares shall be subject to the Repurchase Right set
forth in Section 2 of this Agreement and the restrictions on transfer set forth
in Section 4 of this Agreement. All additional shares of Common Stock acquired
upon any future exercise of the Option shall automatically be deemed to be
Shares (as defined above) subject to all of the terms and conditions of this
Agreement. The Company may indicate the number of such additional shares of
Common Stock on a schedule to this Agreement, appended by the Company and
delivered to the Employee.
2. Repurchase Right.
(a) In the event that the Employee ceases to be employed by the Company for
any reason prior to the third anniversary of the Grant Date, the Company shall
have the right and option (the "Repurchase Right") to purchase from the
Employee, for a sum of $4.80 per share (the "Repurchase Price"), up to that
percentage of the Shares as is set forth in the second column of the table set
forth below opposite the period in which the Employee ceases to be so employed.
PERCENTAGE
OF SHARES
SUBJECT TO
IF CESSATION REPURCHASE
OF EMPLOYMENT OCCURS RIGHT
-------------------- -----
Prior to the first anniversary of
the Grant Date 100%
On or after the first anniversary
but before the second anniversary
of the Grant Date 67%
On or after the second anniversary
but before the third anniversary
of the Grant Date 33%
On or after the third anniversary 0%
I-1
<PAGE>
(b) Upon a Change in Control (as defined below) that occurs after the Employee
has completed one year of employment with the Company, which period may include
employment prior to the Grant Date, the number of Shares as to which the Company
may exercise the Repurchase Right pursuant to Section 2 (a) shall be zero; upon
a Change in Control that occurs after the Employee has completed six months, but
less than one year, of such employment, the number of Shares as to which the
Company may exercise the Repurchase Right pursuant to Section 2(a) shall be
reduced by one-half. For this purpose, a "Change of Control" shall mean any
merger or consolidation of the Company, any tender offer, exchange offer or
other purchase of any outstanding securities of the Company, or any sale of
assets of the Company, if, as a result of such event, the members of the
Company's Board of Directors prior to such event shall thereafter constitute
less than a majority of the Board of Directors of the Company (or of the
surviving or resulting corporation, as the case may be).
(c) Upon the death or disability of the Employee prior to the second
anniversary of the Grant Date, the number of Shares as to which the Company may
exercise the Repurchase Right pursuant to Section 2 (a) shall be reduced by one-
half, and upon the death or disability of the Employee on or after the second
anniversary of the Grant Date but prior to the third anniversary of the Grant
Date, the number of Shares as to which the Company may exercise the Repurchase
Right pursuant to Section 2 (a) shall be zero.
(d) For purposes of this Agreement, employment with the Company shall include
employment with a Parent Corporation or Subsidiary of the Company (as such terms
are defined in the Option Agreement).
(e) Shares which are no longer subject to the Repurchase Right shall be
referred to herein as "Vested Shares" and Shares which are subject to the
Repurchase Right shall be referred to herein as "Unvested Shares".
3. Exercise of Repurchase Right and Closing.
(a) The Company may exercise the Repurchase Right by delivering or mailing to
the Employee (or his estate), in accordance with Section 14, written notice of
exercise within (i) 15 months after the termination of employment of the
Employee with the Company because of death or disability (within the meaning of
Section 105 (d) (4) of the Internal Revenue Code of 1954, as amended (the
"Code")), or (ii) four months after such date in all other cases. Such notice
shall specify the number of Shares to be purchased. If and to the extent the
Repurchase Right is not so exercised within such period, the Repurchase Right
shall automatically expire and terminate effective upon the expiration of such
period.
(b) Within 10 days after his receipt of the Company's notice of the exercise
of the Repurchase Right pursuant to subsection (a) above, the Employee (or his
estate) shall tender to the Company at its principal offices the certificate or
certificates representing the Shares which the Company has elected to purchase,
duly endorsed in blank by the Employee or with duly endorsed stock powers
attached thereto, all in form suitable for the transfer of such Shares to the
Company. Upon its receipt of such Shares, the Company shall deliver or mail to
the Employee a check in the amount of the aggregate Repurchase Price therefor.
(c) After the time at which any Shares are required to be delivered to the
Company for transfer to the Company pursuant to subsection (b) above, the
Company shall not pay any dividend to the Employee on account of such Shares or
permit the Employee to exercise any of the privileges or rights of a stockholder
with respect to such Shares, but shall, in so far as permitted by law, treat the
Company as the owner of such Shares.
(d) The Repurchase Price may be payable, at the option of the Company, in
cancellation of all or a portion of any outstanding indebtedness of the Employee
to the Company or in cash (by check) or both.
I-2
<PAGE>
(e) The Company shall not purchase any fraction of a share upon exercise of
the Repurchase Right, and any fraction of a share resulting from a computation
made pursuant to Section 2 of this Agreement shall be rounded to the nearest
whole share (with any one-half share being rounded upward).
4. Restrictions on Transfer. The Employee hereby agrees that he will not
sell, assign, pledge or otherwise dispose of or encumber any Unvested Shares.
5. Effect of Prohibited Transfer. The Company shall not be required (a) to
transfer on its books any of the Shares which shall have been sold or
transferred in violation of any of the provisions set forth in this Agreement,
or (b) to treat as owner of such Shares or to pay dividends to any transferee to
whom any such Shares shall have been so sold or transferred.
6. Restrictive Legend. All certificates representing Shares shall have
affixed thereto a legend in substantially the following form, in addition to any
other legends that may be required under federal or state securities laws:
"The shares of stock represented by this certificate are subject to
restrictions on transfer and an option to purchase set forth in a certain
Stock Option Exercise Agreement between the corporation and the registered
owner of this certificate (or his predecessor in interest), and such
Agreement is available for inspection without charge at the office of the
Treasurer of the corporation."
7. Adjustments for Stock Splits, Stock Dividends, etc. If from time to time
during the term of the Repurchase Right there is any stock split-up, stock
dividend, stock distribution or other reclassification of the Common Stock of
the Company, any and all new, substituted or additional securities to which the
Employee is entitled by reason of his ownership of the Shares shall be
immediately subject to the Repurchase Right, the restrictions on transfer and
other provisions of this Agreement in the same manner and to the same extent as
the Shares, and the Option Price shall be appropriately adjusted.
8. Escrow. The Employee, simultaneously with the execution of this
Agreement, shall execute and deliver a certain Escrow Agreement substantially
the form of Exhibit I hereto, and shall deliver to the Escrow Agent thereunder
the certificates representing the Shares issued pursuant to this Agreement,
together with two stock powers duly endorsed in blank by the Employee.
9. Withholding Taxes.
(a) The Employee acknowledges and agrees that the Company has the right to
deduct from payments of any kind otherwise due to the Employee any federal,
state or local taxes of any kind required by law to be withheld with respect
to the purchase of the Shares by the Employee.
(b) If the Employee elects, in accordance with Section 83(b) of the Internal
Revenue Code of 1954, as amended, to recognize ordinary income in the year of
acquisition of the Shares, the Company will require at the time of such
election an additional payment for withholding tax purposes based on the
difference, if any, between the purchase price for such Shares and the fair
market value of such Shares as of the day immediately preceding the date of
the purchase of such Shares by the Employee.
10. Severability. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision
of this Agreement, and each other provision of this Agreement shall be severable
and enforceable to the extent permitted by law.
11. Waiver. Any provision contained in this Agreement may be waived, either
generally or in any particular instance, by the Board of Directors of the
Company.
12. Binding Effect. This Agreement shall inure to the benefit of the Company
and its successors and assigns and shall be binding upon the Employee and his
heirs, executors, administrators, legal representatives, successors and assigns,
subject to the restrictions on transfer set forth in Section 4 of this
Agreement.
I-3
<PAGE>
13. No Rights To Employment. Nothing contained in this Agreement Shall be
Construed as giving the Employee any right to be retained, in any position, as
an employee of the Company.
14. Notice. All notices required or permitted hereunder shall be in writing
and deemed effectively given upon personal delivery or upon deposit in the
United States Post Office, by registered or certified mail, postage prepaid,
addressed to the other party hereto at the address shown beneath his or its
respective signature to this Agreement, or at such other address or addresses as
either party shall designate to the other in accordance with this Section 14.
15. Pronouns. Whenever the context may require, any pronouns used in this
Agreement shall include the corresponding masculine, feminine or neuter forms,
and the singular form of nouns and pronouns shall include the plural, and vice
versa.
16. Entire Agreement. This Agreement constitutes the entire agreement
between the parties, and supersedes all prior agreements and understandings,
relating to the subject matter of this Agreement.
17. Amendment. This Agreement may be amended or modified only by a written
instrument executed by both the Company and the Employee.
18. Captions. The captions and paragraph headings contained in this
Agreement are for convenience of reference only and shall not be considered in
construing this Agreement.
19. Governing Law. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the Commonwealth of Massachusetts.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year first above written.
ORGANOGENESIS INC.
By:
------------------------------------
Title:
------------------------------------
Address: 150 Dan Road
Canton, MA 02021
EMPLOYEE
------------------------------------
Address:
I-4
<PAGE>
EXHIBIT I
ORGANOGENESIS INC.
ESCROW AGREEMENT
AGREEMENT made as of this .... day of 19 , among Organogenesis Inc., a
Delaware corporation (the "Company"), the Treasurer of the Company
(the "Escrow Agent") and (the "Employee").
WHEREAS, the Company has granted to the Employee an option (the "Option") to
purchase shares of its Common Stock;
WHEREAS, the Employee has exercised the Option and the Company has issued to
the Employee ...... shares of Common Stock, represented by certificate
no (the "Shares"), pursuant to an Incentive Stock Option Exercise
Agreement of even date herewith (the "Exercise Agreement");
WHEREAS, the Shares are restricted as to transfer and subject to an obligation
of the Employee to offer to resell them to the Company in certain events;
WHEREAS, as an inducement to the Company to grant the Option and to assure
that the Shares are available for delivery to the Company, if necessary, upon
exercise of the Company's Repurchase Right (as defined in the Exercise
Agreement), the Employee has agreed to deposit the Shares in escrow with the
Escrow Agent; and
WHEREAS, the Escrow Agent is willing to hold the Shares in escrow under this
Agreement;
Now, THEREFORE, for valuable consideration, receipt of which is hereby
acknowledged, the parties hereto hereby agree as follows:
1. Deposit of Escrow Shares. Simultaneously with the execution of this
Agreement by the parties hereto, the Employee has deposited the certificate
representing the Shares with the Escrow Agent, to be held by the Escrow Agent in
escrow subject to the terms and conditions of this Agreement. The certificate
for the Shares is accompanied by two separate stock powers executed by the
Employee in blank for transfer.
2. Receipt for Escrow Shares. The Escrow Agent hereby acknowledges receipt
of the Shares pursuant to Section I of this Agreement. The Escrow Agent agrees
to hold the Shares in escrow and to dispose of them as hereinafter provided,
shall not transfer the Shares except in accordance with the provisions of this
Agreement and shall act with respect thereto in accordance with all the terms
and provisions of this Agreement.
3. Delivery and Deposit of Additional Stock; Future Exercise.
(a) The Employee hereby irrevocably authorizes the Company to deliver to the
Escrow, Agent any certificate or certificates representing additional or other
shares of capital stock distributed on, in respect of, or in substitution for
the Shares in the event of any stock dividend, stock split-up, reclassification
or other capital reorganization of the Shares. Such additional or other shares
shall be held in escrow under all the terms and conditions set forth in this
Agreement as if they were originally deposited with the Escrow Agent at the time
of execution of this Agreement.
(b) All additional shares of Common Stock acquired upon any future exercise of
the Option shall automatically be deemed to be Shares (as defined above) subject
to all of the terms and conditions of this Agreement. The Company may indicate
the number of such additional shares of Common Stock on a schedule to this
Agreement, appended by the Company and delivered to the Employer and the Escrow
Agent.
-i-
<PAGE>
4. Voting and Cash Dividends. The right to vote the Shares and to receive
cash dividends on the Shares shall remain in the Employee unless and until the
Shares are purchased by the Company in accordance with the terms of the Award
and this Agreement.
5. Term. The term of this Agreement shall commence on the date of this
Agreement and end on the first date on which none of the Shares are subject to
the Company's Repurchase Right (the "Expiration Date"). On the Expiration
Date, the Escrow Agent shall mail or deliver to the Employee the Shares or the
remainder of such Shares as the Escrow Agent shall then hold pursuant to the
terms of this Agreement (together with all stock powers relating thereto),
unless a claim has been made or is then pending with respect to the remaining
Shares as set forth in this Agreement.
6. Purchase of Unvested Shares. If the Company duly exercises its
Repurchase Right pursuant to the Exercise Agreement, upon the termination of
employment of the Employee with the Company, to purchase any Shares which have
not then become Vested Shares (as defined in the Exercise Agreement), the
Company shall promptly deliver to the Escrow Agent a copy of the notice of
exercise delivered to the Employee pursuant to the Exercise Agreement. The
Escrow Agent is hereby irrevocably authorized and directed, upon receipt of
such notice, (i) to date and complete the stock powers necessary for the
transfer to the Company of the Shares which the Company has duly elected to
purchase, (ii) to deliver such stock powers to the Company, together with the
certificate or certificates representing such Shares, and (iii) to deliver to
the Employee any Shares which the Company has not elected to purchase. Upon
its receipt of the certificate or certificates representing the Shares which
the Company has elected to purchase, together with duly endorsed stock powers,
the Company shall deliver the purchase price therefor to the Employee as
provided in the Exercise Agreement. The Company and the Employee shall furnish
to the Escrow Agent any additional documents or instruments as the Escrow Agent
may reasonably require to effect any transfer of the Shares pursuant to this
Agreement.
7. Delivery of Vested Shares. When, as and if any Shares become Vested
Shares pursuant to the Exercise Agreement, the Escrow Agent shall, at the
written request of the Employee, deliver to the Employee a certificate
representing such Vested Shares. The balance of such Shares (if any) which
have not then become Vested Shares pursuant to the Exercise Agreement will
continue to be held by the Escrow Agent in escrow under this Agreement until
the Expiration Date.
8. Power-of-Attorney. The Employee does hereby irrevocably constitute and
appoint the Escrow Agent as his or her attorney-in-fact to execute all stock
powers, assignments and other documents necessary or appropriate to effect any
transfer or delivery of the Shares, or portion thereof, in accordance with this
Agreement. Such power-of-attorney shall survive the death of the Employee.
9. Responsibilities and Liabilities of the Escrow Agent. The Escrow Agent
shall not be liable under this Agreement for any action taken or omitted in
good faith and in the exercise of the Escrow Agent's own good judgment. The
Escrow Agent shall be obligated only for the performance of such duties as are
specifically set forth in this Agreement and may rely and shall be protected in
relying on or refraining from acting on any instrument reasonably believed by
him to be genuine and to have been signed or presented by the proper party or
parties. The Escrow Agent shall not be liable in any respect on account of the
identity, authorities or rights of the parties executing or delivering or
purporting to execute or deliver any documents deposited or called for under
this Agreement.
10. Successor Escrow Agent. The responsibilities of the Escrow Agent under
this Agreement shall terminate if he shall cease to be the Treasurer of the
Company or if he shall resign by written notice to each party. In the event of
any such termination, the Company shall appoint any officer of the Company as
successor Escrow Agent who shall be entitled to all of the rights and powers of
the Escrow Agent hereunder as if originally named herein as Escrow Agent.
11. Disputes. If any dispute should arise with respect to the delivery
and/or ownership or right of possession of the Shares held by the Escrow Agent
hereunder, the Escrow Agent is authorized and directed to retain in his
possession without liability to anyone all or any part of such Shares until
such
-ii-
<PAGE>
dispute is resolved either by mutual written agreement of the parties concerned
or by a final order, judgment or decree of a court of competent jurisdiction
after the time for appeal has expired and no appeal has been perfected, but the
Escrow Agent shall be under no duty to institute or defend any such proceeding.
12. Indemnity. The Company shall indemnify and hold harmless the Escrow
Agent against any loss, liability or expense imposed upon or incurred by the
Escrow Agent as a result of or in connection with his services under this
Agreement, provided that the Escrow Agent is not adjudged by a court of
competent jurisdiction to have acted with gross negligence or in bad faith.
13. Notices. Any notice required or permitted pursuant to this Agreement
shall be in writing and shall be delivered by hand or by registered or
certified mail, postage prepaid, addressed as follows:
If to the Employee at the address indicated on the last page hereof
If to the Company: Organogenesis Inc.
150 Dan Road
Cambridge, MA 02142
If to the Escrow Agent: Treasurer
c/o Organogenesis Inc.
150 Dan Road
Canton, MA 02021
Any party may change his or its respective address by notice given to the
other party in the manner set forth in this Section 13.
14. Binding Effect. In accordance with its terms, this Agreement shall be
binding upon and inure to the benefit of the parties, their respective
executors, administrators, successors and assigns.
15. Amendments. This Agreement may be amended or modified at any time and
from time to time only in a writing executed by all the parties hereto.
---
16. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts.
17. Counterparts. This Agreement may be executed simultaneously in
counterparts, each of which shall be deemed an original, but all of which
together shall constitute but one agreement binding on the parties.
-iii-
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year first above written.
ORGANOGENESIS INC.
By:
Title:
Address: 150 Dan Road
Canton, MA 02021
EMPLOYEE
Address:
ESCROW AGENT:
Donna L. Abelli
Treasurer, Organogenesis Inc.
-iv-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> JUN-30-1997
<CASH> 1,121
<SECURITIES> 8,184
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 10,175
<PP&E> 14,001
<DEPRECIATION> 6,888
<TOTAL-ASSETS> 17,379
<CURRENT-LIABILITIES> 2,461
<BONDS> 0
0
0
<COMMON> 180
<OTHER-SE> 14,688
<TOTAL-LIABILITY-AND-EQUITY> 17,379
<SALES> 0
<TOTAL-REVENUES> 3,069
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 13,729
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (10,660)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (10,660)
<EPS-PRIMARY> (.59)
<EPS-DILUTED> (.59)
</TABLE>
